Pioneering biophotonics technology is the first screening method to detect the early presence of ovarian cancer in humans
An international research collaboration has found five new regions of the human genome that are linked to increased risks for developing ovarian cancer.
A new gentler chemotherapy drug has been designed to be less toxic to a young woman's fertility. This is the first cancer drug tested while in development for its effect on fertility using a novel in vitro test.
A two-step immunotherapy approach and the experimental antibody-drug conjugate DMUC5754A show promise for advanced ovarian cancer, according to research presented at AACR 2013.
At no age is there an overall survival benefit associated with bilateral oophorectomy compared with ovarian conservation at the time of hysterectomy for benign disease.
Shift work may be associated with an increased risk of ovarian cancer, according to a study published in the April issue of Occupational & Environmental Medicine.
IP chemo improves long-term survival in advanced disease versus intravenous therapy
A phase II clinical trial provides the first evidence of a relatively high response rate in patients with low-grade serous ovarian cancer receiving the drug selumetinib.
After expedited review, the FDA okays the first generic version of Doxil (doxorubicin hydrochloride liposome injection), now in short supply.
A two-step personalized immunotherapy therapy treatment, which involved a dendritic cell vaccine using the patient's own tumor followed by adoptive T-cell therapy, triggered antitumor immune responses in four of six patients.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|